FDA Approves AZULFIDINE EN-TABS — Pfizer Laboratories Div Pfizer Inc
Pfizer today announced FDA approval of AZULFIDINE EN-TABS (sulfasalazine), completing the corporate restructuring of the antibiotic’s assets. This segregation opens a significant revenue stream for Pfizer while intensifying competition with generic manufacturers currently serving the widespread Ulcerative Colitis market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed